Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Crohn Disease: HELP
Articles by Kaushik Patra
Based on 1 article published since 2010
(Why 1 article?)

Between 2010 and 2020, Kaushik Patra wrote the following article about Crohn Disease.
+ Citations + Abstracts
1 Clinical Trial Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. 2017

Sands, Bruce E / Chen, Jingjing / Feagan, Brian G / Penney, Mark / Rees, William A / Danese, Silvio / Higgins, Peter D R / Newbold, Paul / Faggioni, Raffaella / Patra, Kaushik / Li, Jing / Klekotka, Paul / Morehouse, Chris / Pulkstenis, Erik / Drappa, Jörn / van der Merwe, René / Gasser, Robert A. ·Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: bruce.sands@mssm.edu. · MedImmune, Gaithersburg, Maryland. · Robarts Clinical Trials, University of Western Ontario, London, Ontario. · MedImmune, Cambridge, United Kingdom. · Humanitas Clinical and Research Center, Milan, Italy. · University of Michigan, Ann Arbor, Michigan. · MedImmune, Mountain View, California. · Amgen, Thousand Oaks, California. ·Gastroenterology · Pubmed #28390867.

ABSTRACT: BACKGROUND & AIMS: MEDI2070 is a human monoclonal antibody that selectively inhibits interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn's disease (CD). We analyzed its safety and efficacy in treatment of CD in a phase 2a study. METHODS: We conducted a double-blind, placebo-controlled study of 119 adults with moderate to severe CD failed by treatment with tumor necrosis factor antagonists. Patients were randomly assigned (1:1) to groups given MEDI2070 (700 mg) or placebo intravenously at weeks 0 and 4. Patients received open-label MEDI2070 (210 mg) subcutaneously every 4 weeks from weeks 12 to 112. The CD Activity Index was used to measure disease activity. RESULTS: The primary outcome, clinical response (either a 100-point decrease in CD Activity Index score from baseline or clinical remission, defined as CD Activity Index score <150) at week 8 occurred in 49.2% of patients receiving MEDI2070 (n = 59) compared with 26.7% receiving placebo (n = 60; absolute difference, 22.5%; 95% confidence interval, 5.6%-39.5%; P = .010). Clinical response at week 24 occurred in 53.8% of patients who continued to receive open-label MEDI2070 and in 57.7% of patients who had received placebo during the double-blind period and open-label MEDI2070 thereafter. The most common adverse events were headache and nasopharyngitis. Higher baseline serum concentrations of IL22, a cytokine whose expression is induced by IL23, were associated with greater likelihood of response to MEDI2070 compared with placebo. CONCLUSIONS: In a phase 2a trial of patients with moderate to severe Crohn's disease who had failed treatment with tumor necrosis factor antagonists, 8 and 24 weeks of treatment with MEDI2070 were associated with clinical improvement. ClinicalTrials.gov ID: NCT01714726.